rs121913444
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs121913428
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.
|
23102728 |
2013 |
rs121913444
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.
|
23102728 |
2013 |
rs121913465
|
|
T |
0.700 |
GeneticVariation |
CLINVAR |
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.
|
23102728 |
2013 |
rs397517097
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.
|
23102728 |
2013 |
rs121913428
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
|
22753918 |
2012 |
rs121913444
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
|
22753918 |
2012 |
rs121913465
|
|
T |
0.700 |
GeneticVariation |
CLINVAR |
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
|
22753918 |
2012 |
rs397517097
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
|
22753918 |
2012 |
rs150036236
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.
|
20942962 |
2010 |
rs1057519847
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A subsequent advanced SCC bearing EGFR L858R/T790M mutations occurred 3 years after surgery.
|
28272214 |
2017 |
rs1057519848
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A subsequent advanced SCC bearing EGFR L858R/T790M mutations occurred 3 years after surgery.
|
28272214 |
2017 |
rs121434568
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A subsequent advanced SCC bearing EGFR L858R/T790M mutations occurred 3 years after surgery.
|
28272214 |
2017 |